Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | SLXN Stock NewsStockTitan·Aug 13 at 11:45 PMSLXN-4.74%
12 Industrials Stocks Moving In Wednesday's Intraday Sessionbenzinga_article·Aug 12 at 12:05 PMATRO-6.92%ELOG+1.70%
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga_article·Aug 12 at 07:06 AMSILO+4.23%SLXN-4.74%
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering | SLXN Stock NewsStockTitan·Aug 11 at 11:01 AMSLXN-4.74%
Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancersPUBT·Aug 9 at 07:41 AMSLXN-4.74%
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga_article·Aug 7 at 04:05 PMABCL-1.03%NXTC-14.20%
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers | SLXN Stock NewsStockTitan·Aug 4 at 12:15 AMSLXN-4.74%
Silexion reports preclinical SIL204 data supporting Phase 2/3 development in KRAS-driven cancersPUBT·Aug 4 at 08:16 AMSLXN-4.74%
